EPCAM and breast cancer: Ongoing clinical trials are investigating new-generation CAR-T cells targeting CD44v6 (NCT04430595) and EpCAM (NCT02915445) surface antigens as a safe, feasible, and effective intervention for advanced BC [138,139].